Essig is board member of several large US-based life science companies, as well as a former senior healthcare investment banker and managing director at Goldman Sachs.
He currently serves as chairman of Nasdaq-listed Integra Life Sciences, which he built during his tenure as CEO to more than $800m in revenues and $1.6bn in enterprise value. Prior to Integra, he supervised the medical technology practice at Goldman Sachs, where he had served for ten years as a senior merger and acquisitions advisor to a broad range of international medical technology, pharmaceutical and biotechnology clients. He is a member of the board of directors of St. Jude Medical Corporation and chairman of Breg.
“I am excited to work with Wellington Partners, a leading European venture capital firm in the life sciences sector, which is also well recognized and respected in the US”, Essig said. “Over the last couple of years, I have seen the Wellington life science team building an outstanding portfolio with many potential future sector leaders.”
The firm’s Wellington Partners IV Life Science recently had a first closing and is intended to be further enlarged to a target size of €120m.
With more than €800m under management and offices in Munich, London and Zurich, Wellington Partners invests in digital media, resource efficiency and life sciences.
Copyright © 2013 AltAssets